Shilpa Medicare Ltd vs Vivanza Biosciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Shilpa Medicare Ltd is ₹ 442.1 as of 06 May 15:30 . The P/E Ratio of Shilpa Medicare Ltd changed from 18.4 on March 2021 to 82.8 on March 2025 . This represents a CAGR of 35.10% over 5 yearsThe P/E Ratio of Vivanza Biosciences Ltd changed from 687.4 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Shilpa Medicare Ltd changed from ₹ 2721 crore on March 2021 to ₹ 6483 crore on March 2025 . This represents a CAGR of 18.96% over 5 yearsThe Market Cap of Vivanza Biosciences Ltd changed from ₹ 52.24 crore on March 2021 to ₹ 7.96 crore on March 2025 . This represents a CAGR of -31.36% over 5 years The revenue of Shilpa Medicare Ltd for the Dec '25 is ₹ 410.54 crore as compare to the Sep '25 revenue of ₹ 371.72 crore. This represent the growth of 10.44% The revenue of Vivanza Biosciences Ltd for the Dec '25 is ₹ 45.33 crore as compare to the Sep '25 revenue of ₹ 55.37 crore. This represent the decline of -18.13% The ebitda of Shilpa Medicare Ltd for the Dec '25 is ₹ 101.9 crore as compare to the Sep '25 ebitda of ₹ 109.92 crore. This represent the decline of -7.3% The ebitda of Vivanza Biosciences Ltd for the Dec '25 is ₹ 0.29 crore as compare to the Sep '25 ebitda of ₹ 0.61 crore. This represent the decline of -52.46% The net profit of Shilpa Medicare Ltd changed from ₹ 14.06 crore to ₹ 44.58 crore over 7 quarters. This represents a CAGR of 93.36% The net profit of Vivanza Biosciences Ltd changed from ₹ 0.27 crore to ₹ 0.2 crore over 7 quarters. This represents a CAGR of -15.76% The Dividend Payout of Shilpa Medicare Ltd changed from 4.86 % on March 2021 to 14.01 % on March 2025 . This represents a CAGR of 23.58% over 5 yearsThe Dividend Payout of Vivanza Biosciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987.
The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.
It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.

About Vivanza Biosciences Ltd

Vivanza Biosciences Limited, formerly known as Ivee Injectaa Limited was established in March, 1982 as a Private Limited Company and was converted into a Public Limited Company in May, 1992.
Due to recessionary trends which lead to difficult business conditions in year 1999-2000, the parenteral industry suffered a setback and due to this, the name of the Company was changed from Ivee Injectaa Limited to Vivanza Biosciences Limited in 2015. The Company is focused in commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines.
It is presently engaged in the business of Pharmaceutical Products. Head quartered in Gujarat, India, Company came into existence in April 2016 to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system.

FAQs for the comparison of Shilpa Medicare Ltd and Vivanza Biosciences Ltd

Which company has a larger market capitalization, Shilpa Medicare Ltd or Vivanza Biosciences Ltd?

Market cap of Shilpa Medicare Ltd is 8,646 Cr while Market cap of Vivanza Biosciences Ltd is 8 Cr

What are the key factors driving the stock performance of Shilpa Medicare Ltd and Vivanza Biosciences Ltd?

The stock performance of Shilpa Medicare Ltd and Vivanza Biosciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Shilpa Medicare Ltd and Vivanza Biosciences Ltd?

As of May 6, 2026, the Shilpa Medicare Ltd stock price is INR ₹442.1. On the other hand, Vivanza Biosciences Ltd stock price is INR ₹2.0.

How do dividend payouts of Shilpa Medicare Ltd and Vivanza Biosciences Ltd compare?

To compare the dividend payouts of Shilpa Medicare Ltd and Vivanza Biosciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.